STACK · ◇ Layered protocol · 4 tiers
Gut & GI Repair.
BPC-157 was discovered in gastric juice — this is the stack it was made for.
Layered · additive + rotation
Hook facts
The science, in one line each.
BPC-157 was discovered because scientists were puzzled by the stomach's ability to constantly regenerate its own lining despite bathing in acid strong enough to dissolve metal — they found this peptide living inside that acid, protecting and rebuilding tissue, and realised they could extract and use it therapeutically.
BPC-157 is derived from a protein naturally present in human gastric juice — the same fluid that digests food — and it's so stable in stomach acid that it remains intact and active when swallowed, which is why it's the rare peptide that actually works orally, not just by injection.
When to skip it
Read this first.
Active GI bleeding, bowel obstruction, or undiagnosed GI symptoms without medical workup — these are contraindications to peptide-based gut protocols and require conventional medical assessment first. This stack is not a substitute for physician-directed IBD management.
Always cleared with your concierge before protocol start.
Why this works
The strongest evidence.
BPC-157 was originally isolated from human gastric juice — it is the gut's own endogenous repair signal, not an exogenous molecule adapted from another application. In controlled preclinical studies, BPC-157 outperformed omeprazole in healing NSAID-induced gastric ulcers, reduced intestinal anastomosis leakage rates post-surgery, and protected the gut-vascular barrier against chemotherapy-induced damage. Crucially, BPC-157 achieves these effects without receptor desensitisation or acid-rebound risk — it works on the structural and vascular level rather than the secretory level, which makes it mechanistically distinct from every conventional GI therapeutic currently in standard use. The same compound class that Sikiric's research group has demonstrated across musculoskeletal applications (tendons, ligaments, bone) operates through the same angiogenic and growth factor mechanisms in gut tissue — underlining that BPC-157 is a systemic tissue-repair signal whose gut affinity is simply a reflection of where it was first found. KPV's evidence base, while smaller, is focused specifically on gut inflammation: in colitis models, KPV reduces mucosal cytokine levels and preserves epithelial barrier integrity through α-MSH-adjacent anti-inflammatory signalling pathways. The two compounds address different points in the same disease process.
Layered protocol
Choose your tier.
A layered protocol — most tiers add to the last, with a fork or rotation where the data calls for it.
Gut Lining Repair
BPC Spray
The cleanest entry for GI-localised complaints — IBS, bloating, mucosal irritation, acid reflux, and leaky gut patterns…
BPC-157 was originally isolated from gastric juice — the gut is its native terrain. Oral spray delivers BPC-157 directly to the intestinal lining where it stimulates mucosal repair, reinforces the gut-vascular barrier, and begins quieting the inflammatory signal. No injection required. This is the cleanest entry point for IBS, bloating, post-NSAID damage, or any gut complaint where you want the peptide acting where it matters most.
Who it's for
Users with active GI complaints wanting the simplest, most direct entry point. Oral spray delivers BPC-157 directly to the intestinal lining where it does its best work — no injection required.
What to expect
Reduced bloating, improved transit, and early mucosal repair within 7–14 days of consistent twice-daily use. The oral route is highly effective for GI-localised effect and is the cleanest place to start before deciding whether to add injectable coverage.
Gut + Inflammation
BPC Spray
The cleanest entry for GI-localised complaints — IBS, bloating, mucosal irritation, acid reflux, and leaky gut patterns…
BPC-157
Established or systemic gut inflammation patterns where oral spray's local effect needs to be backed up by deeper gut-va…
Oral spray targets the mucosal surfaces it touches directly. Injectable BPC-157 covers the systemic gut-vascular barrier — the deeper structural layer that spray concentrations alone don't reach. These are two different delivery axes for the same repair signal, and running both simultaneously is not redundant: oral for local mucosal contact, injectable for full gut-wall angiogenesis and barrier restoration. The pairing closes the anatomical gap that a single-route protocol leaves open. For users with KPV access, KPV adds the explicit anti-inflammatory complement — BPC repairs the lining; KPV dampens the inflammatory signalling driving the damage. The two peptides act at different points in the gut-inflammation cascade.
Who it's for
Users who want both oral localised effect and systemic injectable coverage. The dual-route BPC protocol for established or systemic gut inflammation patterns.
What to expect
Injectable BPC-157 adds full gut-vascular barrier coverage and faster structural repair across the entire GI tract, not just the surfaces the spray touches. Established inflammation patterns typically respond more completely to the combined route approach by week 4–6.
Full GI Reset
BPC Spray
The cleanest entry for GI-localised complaints — IBS, bloating, mucosal irritation, acid reflux, and leaky gut patterns…
BPC-157
Established or systemic gut inflammation patterns where oral spray's local effect needs to be backed up by deeper gut-va…
TB-500
Chronic GI inflammation, post-surgical gut recovery, and cases involving deep connective-tissue involvement alongside mu…
TB-500 adds the structural layer beneath the mucosa — systemic angiogenesis, stem cell mobilisation, and connective-tissue repair that neither BPC formulation reaches with the same intensity. BPC oral + injectable covers the lining; TB-500 rebuilds the scaffold underneath it. The complete protocol for chronic GI inflammation patterns, post-surgical recovery, or cases where mucosal repair alone isn't holding ground against deeper connective-tissue involvement.
Who it's for
Chronic GI inflammation, post-surgical gut recovery, chronic NSAID damage, or cases where deep connective-tissue repair is needed alongside mucosal healing.
What to expect
TB-500's angiogenic and tissue-regeneration signal adds structural depth to the gut-repair stack by week 6–8. Complete protocol for chronic GI inflammation or post-surgical recovery. Most durable outcomes emerge at week 10–12.
Gut-Immune Axis
Cadence — 20-day Thymalin pulse, then 4-week rest, repeat as needed
+ sits on top of any tier above
Thymalin
Users with autoimmune-adjacent gut patterns — IBD, inflammatory bowel, gut-immune crossover, or cases where gut inflamma…
For gut inflammation with an autoimmune-adjacent driver, the core repair peptides are not enough on their own — you also need to address the immune signal sustaining the damage. Thymalin's 20-day pulse restores thymic immune balance and modulates the regulatory T-cell response without continuous immunomodulation. Pulse Thymalin on top of whichever core tier you're running: 20 days on, 4 weeks rest, then repeat as needed — typically 2 cycles per year. The reason for pulse rather than continuous dosing: Thymalin's regulatory effect is a reset, not a maintenance drug. Running it as a defined course preserves the signal's potency and aligns with how thymic bioregulators are used in the clinical bioregulator literature.
Who it's for
Users with autoimmune-adjacent gut patterns — IBD, inflammatory bowel, gut-immune crossover — who need a thymic immune layer alongside gut repair. Run this tier on top of any core stack tier.
What to expect
Thymalin's 20-day bioregulator pulse adds thymic immune restoration alongside the gut repair protocol. Most effective when gut inflammation is driven by immune dysregulation rather than purely mechanical damage. Typically 2 pulse cycles per year is sufficient.
Compound roster
Every compound, briefed.
Each compound in this stack — what it does and where it fits.
BPC-157 oral spray delivers the peptide directly to the mucosal surfaces it touches — gut lining, oral cavity, oesophagus — at a local concentration that injectable BPC-157 alone doesn't replicate. BPC-157 was originally isolated from human gastric juice and is the gut's own endogenous repair signal: it stimulates mucosal angiogenesis, upregulates growth factor pathways, and reinforces the gut-vascular barrier. Oral delivery bypasses the systemic circulation for GI-localised complaints — making it the most direct entry point for upper-GI symptoms, mucosal repair, and everyday gut maintenance. The absorbed systemic fraction is lower than injection, so spray and injectable are complementary rather than interchangeable.
Best for · The cleanest entry for GI-localised complaints — IBS, bloating, mucosal irritation, acid reflux, and leaky gut patterns where direct mucosal delivery is preferred. Also suitable as a maintenance protocol at lower frequency once an acute course is complete.
Injectable BPC-157 delivers the peptide systemically, providing full gut-vascular barrier coverage that oral spray cannot match on its own. BPC-157 acts by promoting angiogenesis at the gut wall, activating the growth factor signalling cascade (including EGR-1 and VEGF pathways), and restoring tight-junction integrity in intestinal epithelium. Unlike proton pump inhibitors, BPC-157 achieves gastric protection without acid rebound or receptor desensitisation — it works on the structural and vascular level rather than the secretory level. It is the anchor compound for this stack because no other single peptide covers both mucosal repair and gut-vascular barrier restoration at the same time.
Best for · Established or systemic gut inflammation patterns where oral spray's local effect needs to be backed up by deeper gut-vascular repair — IBD, chronic leaky gut, post-surgical GI recovery, chemotherapy-adjacent gut damage. Run alongside BPC-spray for dual-route coverage.
Thymosin Beta-4 (TB-500) acts systemically by upregulating G-actin, mobilising circulating stem cells toward damaged tissue, and reducing whole-body inflammatory load through down-regulation of inflammatory cytokines. In the gut context, TB-500 addresses the deeper connective-tissue and vascular layer that BPC-157's mucosal focus doesn't reach with the same intensity — it's the structural repair depth added to BPC's mucosal signal. The two peptides target complementary layers of the gut-repair cascade: BPC-157 drives the lining back together from the inside; TB-500 rebuilds the vascular and connective scaffold that holds that lining in place under inflammatory stress.
Best for · Chronic GI inflammation, post-surgical gut recovery, and cases involving deep connective-tissue involvement alongside mucosal damage. Best as a Pro-tier addition on top of BPC oral + injectable rather than a standalone gut compound.
Thymalin is a thymic bioregulator peptide that restores thymic function and regulates T-lymphocyte balance — the immune layer most relevant to gut-immune crossover patterns. In the gut context, thymic immune restoration is the mechanism that addresses autoimmune-adjacent gut inflammation: where the immune system is actively attacking or over-responding to intestinal epithelium, Thymalin's modulation of regulatory T-cell populations provides a reset the other three peptides in this stack cannot offer. Crucially, Thymalin is run in pulse cycles rather than continuously, which preserves its regulatory effect and avoids receptor habituation — the same logic behind how thymic peptides are used clinically in immunosenescence protocols.
Best for · Users with autoimmune-adjacent gut patterns — IBD, inflammatory bowel, gut-immune crossover, or cases where gut inflammation persists despite BPC-focused repair protocols. Run as an adjunct pulse on top of the core gut stack, 2 cycles per year.
The science
Peer-reviewed findings.
Key research findings from the compounds in this stack.
BPC-157 is uniquely stable in human gastric juice — it was originally isolated from it — making it one of the only therapeutic peptides that retains biological activity after oral ingestion, a property confirmed across multiple studies by Sikiric et al. and validated in IBD clinical trials
SOURCE · PMC7096228 — Stable Gastric Pentadecapeptide BPC 157; Sikiric P et al., multiple publications
Oral and intragastric administration of BPC-157 demonstrates protective effects against alcohol-induced gastric mucosal damage, NSAID-induced ulceration, and inflammatory bowel conditions — with the same equipotent dosing range as injectable routes for GI-specific indications
SOURCE · Frontiers in Pharmacology 2021 (PMC): Stable Gastric Pentadecapeptide BPC 157 and Wound Healing; Becejac et al. 2018, J Physiol Pharmacol
BPC-157 significantly upregulates growth hormone receptor expression in tendon fibroblasts in a dose- and time-dependent manner, explaining its consistent ability to accelerate tendon-to-bone healing across multiple injury models
SOURCE · PMC6271067 — Frontiers in Pharmacology / PubMed Central; Chang et al., tendon outgrowth studies
In clinical trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736), BPC-157 demonstrated safety in human subjects with no dose-limiting toxicity — the LD1 was never achieved even at high doses, making it one of the most safety-studied experimental peptides
SOURCE · ResearchGate / Sikiric et al.; PubMed 17713731
Protocol
How to run it.
Frequency
BPC-157 oral spray: 250–500 mcg sublingually or swallowed, twice daily (morning and evening on empty stomach for GI-localised effect). BPC-157 injectable: 250–500 mcg subcutaneous once daily, near-abdominal injection site for gut focus. TB-500: 2–5 mg subcutaneous 2–3x per week during loading (Weeks 1–4), then 2 mg once weekly maintenance. Thymalin (adjunct pulse): 5–10 mg subcutaneous daily for 20 consecutive days.
Duration
4–8 weeks for acute GI inflammation or post-procedure recovery. 8–12 weeks for chronic conditions. Oral BPC spray can be continued long-term at lower frequency as a maintenance protocol. Thymalin adjunct: 20-day active pulse, then rest — see cycling below.
Timing
Oral BPC spray on an empty stomach for maximum mucosal absorption — first thing in the morning and 30 minutes before bed. Injectable BPC-157 timing is flexible; peri-abdominal injection pre-meal is common in gut-focused protocols. TB-500 timing is not critical — mornings work well. Thymalin can be dosed any time of day during the 20-day pulse.
Cycling
Foundation (oral spray only): can be run continuously at low doses as maintenance. Standard: 8 weeks on, 4 weeks off, reassess. Pro: 8–12 weeks per cycle, 4-week break. Adjunct (Thymalin pulse): 20-day active course, 4-week rest, repeat as needed — typically 2 cycles per year for autoimmune-adjacent patterns.
Who it's for
Your profile.
Anyone dealing with chronic GI complaints — IBS, IBD, leaky gut, SIBO patterns, post-NSAID or post-antibiotic gut damage, acid reflux, or slow transit. BPC-157 was originally isolated from human gastric juice; the gut is its native terrain. This stack is also well-suited for users who notice that gut dysfunction is the upstream driver of their inflammation, immune dysregulation, or even cognitive performance — the gut-brain axis is real and so is gut-immune crossover. Athletes who have damaged their gut lining through NSAID overuse, extreme training volume, or poor dietary practices are a core audience.
Timeline
What to expect.
- 01
Week 1–2
Oral BPC spray typically produces the fastest symptom relief — reduced bloating, improved stool consistency, less post-meal discomfort within 7–14 days of consistent twice-daily use. Injectable BPC-157 users often report more rapid systemic effects. The active inflammatory phase begins to quiet during this window.
- 02
Week 6
Meaningful mucosal repair and barrier function restoration. IBS and IBD users typically see significant reduction in active symptoms. Injectable users report improved energy and reduced systemic inflammation signals. Gut-brain axis benefits — clearer thinking, reduced anxiety — become noticeable for users with strong gut-cognitive crossover.
- 03
Week 12
Structural gut lining restoration for chronic cases. Users with long-standing leaky gut patterns report durable symptom resolution. Post-antibiotic or post-NSAID damage typically fully resolved. TB-500 users see deep connective-tissue repair depth that oral BPC alone cannot achieve.
Stacking notes
How this combines.
BPC-157 and KPV (Lys-Pro-Val) are the canonical pairing in the gut-healing literature — but they are complementary mechanisms, not redundant ones. BPC-157 drives structural repair: angiogenesis at the gut wall, tight-junction restoration, growth factor signalling that rebuilds damaged mucosa. KPV acts at a different point in the gut-inflammation cascade — it is a tripeptide derived from the C-terminal of α-MSH, and its primary action is dampening the mucosal inflammatory signal directly. BPC fixes the tissue; KPV quiets the inflammation driving the damage. Running KPV alongside BPC-157 addresses both stages simultaneously rather than just one. Within the current catalogue, oral BPC spray and injectable BPC-157 cover the two delivery axes — oral for direct mucosal contact in the upper GI, injectable for systemic gut-vascular barrier coverage. These are anatomically complementary, not duplicative. TB-500 adds connective-tissue and angiogenic depth at the structural layer beneath the mucosa. Thymalin targets the immune axis specifically — reserve it for cases where gut inflammation has an autoimmune-adjacent driver. Note: KPV will slot into the Standard tier when added to the catalogue, giving the explicit anti-inflammatory complement its own dedicated position.